Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of BAY 1213790 for venous thromboembolism prevention after elective total knee arthroplasty
MOH_2017-09-17_000483Phase 2Completed
- Sponsor
- Bayer
- Start
- Sep 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of osocimab in venous thromboembolism (VTE) (5 arms), sponsored by Bayer. Started Sep 2017; status: completed.
02
Drugs
osocimab
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on MOH_2017-09-17_000483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-09-17_000483.